Objective To study the clinical efficacy and safety of S-1 versus Gemcitubine in patients with ad-vanced pancreatic cancer .Methods Forty-one elderly patients with advanced pancreatic cancer were randomly divided in -to two groups.The experiment group(21 cases)were treated with S-1 alone,S-1 capsules daily 80 mg/m2, 2 times,d1-14, the control group(20 cases) were treated with Gemcitubine 1000 mg/m2 intravenous drip,d1,8;21 days as 1 cycle.Re-sults The disease control rate of experiment group was 52.3%,and 55%of control group , there was no significant differ-ence(P>0.05).The main adverse reactions were hematology toxicity and gastrointestinal reaction , the drug-related ad-verse reactions in S-1 group were lower than those in Gemcitubine group , there was significant difference ( P<0.05) .Con-clusions S-1 is a safe, effective and convenience chemotherapy of elderly patients with advanced pancreatic cancer .%目的：对比替吉奥与吉西他滨一线治疗老年晚期胰腺癌的临床疗效和安全性。方法41例老年晚期胰腺癌患者，采用随机对照试验分为两组，试验组21例，采用替吉奥单药治疗：替吉奥胶囊80 mg／（ m2· d），分2次，餐后口服，第1～14天；对照组20例，采用吉西他滨单药治疗：吉西他滨1000 mg／m2，静脉滴注，第1，8天；21 d为1个周期。结果试验组疾病控制率为52.3％；对照组为55％，两组比较差异未见统计学意义（ P＞0.05）。主要不良反应为消化道反应和血液学毒性；试验组Ⅲ～Ⅳ度骨髓抑制明显低于对照组，差异有统计学意义（P＜0.05）。结论替吉奥对比吉西他滨一线治疗老年晚期胰腺癌疗效相当，替吉奥组不良反应较吉西他滨组低，耐受性好，可推荐作为老年晚期胰腺癌的一线化疗方案。
展开▼
